The date

Welcome to the ICON8 Trials Programme website

This website is designed to provide information about the ICON8 Trials Programme encompassing ICON8 and ICON8B for both patients and collaborators.

ICON8 is a randomised three-arm, three stage Gynaecologic Cancer InterGroup (GCIG) phase III trial designed to evaluate the safety and efficacy of dose-dense, dose-fractionated carboplatin-paclitaxel chemotherapy in the treatment of patients with ovarian cancer.

 

Learn more about ICON8:

 

 

 

 

 

 

 

 

 

 

 

 ICON8B is a randomised 3-arm, Gynaecologic Cancer Intergroup (GCIG) phase III trial investigating the combination of dose-fractionated chemotherapy and bevacizumab compared to either strategy alone for the first-line treatment of women with newly diagnosed high-risk stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer.

Learn more about ICON8B:

 

 

Accrual

ICON8B Accrual Update

The latest accrual figures for February 2018 have been released.

The total numbers recruited:

464/ 660

across all the regions.

Register Interest